ASX Announcement

17 December 2025

Successful Completion of First Hot Production Run at Sydney Facility

Sydney, Australia – 17 December 2025: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first hot (radio-activated) production test run at its Sydney manufacturing facility has been successfully completed.

The hot production test run was a formal manufacturing build in which the OncoSil™ device was produced using standard production facilities, equipment, materials and processes, rather than trial or test setups.

The successful completion of the Company's first hot production test run at its new Sydney manufacturing facility represents an important, risk-managed milestone. It demonstrates the facility's capability to manufacture the already approved OncoSil™ device under full production conditions and supports the ongoing regulatory review process for the facility. Regulatory approval for the facility is expected in H2 CY2026, subject to the completion of required regulatory processes and the satisfaction of all applicable regulatory requirements.

This milestone supports OncoSil Medical's strategy to strengthen its internal manufacturing capabilities and enhance supply chain resilience as the Company advances its commercial and clinical programs. Subject to regulatory approval and ongoing operational performance, the Company expects the new facility to deliver manufacturing efficiencies and lower unit production costs over time, which are anticipated to support improved gross product margins.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Successfully completing our first hot production test run marks a significant milestone for OncoSil Medical. It instils confidence in our manufacturing capabilities and confirms that our Sydney facility is fully equipped to meet future production needs. Crucially, this achievement also plays a key role in advancing our regulatory efforts as we continue working to finalise the outstanding manufacturing-related regulatory requirements."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	**Mr. Tim Luscombe & Mr. David Wood** Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year[1]. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Turkey, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. https://gco.iarc.fr/en